Autifony Therapeutics
Autifony are dedicated to developing new medicines to treat rare genetic CNS disorders
Autifony are dedicated to developing new medicines to treat rare genetic CNS disorders
Autifony Therapeutics, founded in 2011, is dedicated to developing new medicines to treat rare genetic CNS disorders. The company's slogan "Autifony are dedicated to developing new medicines to treat rare genetic CNS disorders" encapsulates its mission. Specializing in Biotechnology, Health and Wellness, and Medical Devices, Autifony utilizes its pioneering ion channel drug discovery platform. The company recently received a £1.30M Venture Round investment on 15 March 2017 from Innovate UK. This funding will likely further its research and development efforts as it continues to pursue innovative treatments for rare genetic CNS disorders.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | £1.30M | 1 |
|
15 Mar 2017 |
| Series A | £8.00M | 5 |
|
10 Jul 2015 |
| Grant | £2.20M | - | 04 Jun 2014 | |
| Series A | $5.50M | - | 04 Jun 2013 | |
| Seed Round | £10.00M | 2 |
|
22 Aug 2011 |
No recent news or press coverage available for Autifony Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
